Sotera Health Company (SHC) Bundle
Understanding Sotera Health Company (SHC) Revenue Streams
Understanding Sotera Health Company’s Revenue Streams
As of September 30, 2024, Sotera Health Company reported total net revenues of $810,238 thousand, reflecting an increase of $71,189 thousand or 9.6% compared to $739,049 thousand for the same period in 2023.
Breakdown of Primary Revenue Sources
The revenue sources for the nine months ended September 30, 2024, are as follows:
| Revenue Type | 2024 (Thousands) | 2023 (Thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| Service | $703,027 | $667,680 | $35,347 | 5.3% |
| Product | $107,211 | $71,369 | $35,842 | 50.2% |
| Total Net Revenues | $810,238 | $739,049 | $71,189 | 9.6% |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for the nine months ended September 30, 2024, shows a robust increase:
- Service Revenue Growth: Increased by $35,347 thousand or 5.3%.
- Product Revenue Growth: Increased by $35,842 thousand or 50.2%.
This indicates a strong performance in product sales, particularly driven by volume and favorable pricing.
Contribution of Different Business Segments to Overall Revenue
The contribution of various segments to total net revenues for the nine months ended September 30, 2024 is categorized as follows:
| Segment | Net Revenues (Thousands) | Percentage of Total Revenues |
|---|---|---|
| Sterigenics | $518,425 | 64.0% |
| Nordion | $116,564 | 14.4% |
| Nelson Labs | $175,249 | 21.6% |
Analysis of Significant Changes in Revenue Streams
For the nine months ended September 30, 2024, the notable changes in revenue streams include:
- Sterigenics: Revenues rose by $23,491 thousand or 4.7% compared to the previous year.
- Nordion: Revenues surged by $35,940 thousand or 44.6%, attributed to favorable pricing and increased volume.
- Nelson Labs: Revenues increased by $11,758 thousand or 7.2%, driven by volume and pricing improvements.
A Deep Dive into Sotera Health Company (SHC) Profitability
A Deep Dive into Sotera Health Company's Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit was $437,930 thousand, representing a gross profit margin of approximately 54.1%. This compares to a gross profit of $397,075 thousand for the same period in 2023, which was a margin of 53.7%.
Operating Profit Margin: The operating income for the nine months ended September 30, 2024 stood at $210,480 thousand, leading to an operating profit margin of about 25.9%. In contrast, for the nine months ended September 30, 2023, the operating income was $172,668 thousand, reflecting a margin of 23.4%.
Net Profit Margin: The net income for the nine months ended September 30, 2024 was $32,075 thousand, translating into a net profit margin of approximately 4.0%. This is an increase from the net income of $12,695 thousand reported for the nine months ended September 30, 2023, which had a net profit margin of 1.7%.
| Metric | 9 Months Ended September 30, 2024 | 9 Months Ended September 30, 2023 | Change |
|---|---|---|---|
| Gross Profit | $437,930 | $397,075 | $40,855 |
| Gross Profit Margin | 54.1% | 53.7% | 0.4% |
| Operating Income | $210,480 | $172,668 | $37,812 |
| Operating Profit Margin | 25.9% | 23.4% | 2.5% |
| Net Income | $32,075 | $12,695 | $19,380 |
| Net Profit Margin | 4.0% | 1.7% | 2.3% |
Trends in Profitability: Over the past year, there has been a noticeable improvement in profitability metrics. The gross profit margin has increased by 0.4%, the operating profit margin has improved by 2.5%, and the net profit margin has surged by 2.3%.
Comparison with Industry Averages: The company’s gross profit margin of 54.1% exceeds the industry average of approximately 45%. The operating profit margin of 25.9% is also favorable compared to the industry average of 20%. However, the net profit margin of 4.0% trails behind the industry average of about 5%.
Operational Efficiency Analysis: The total operating expenses for the nine months ended September 30, 2024 were $227,450 thousand, representing an increase of 1.4% from $224,407 thousand in 2023. This indicates effective cost management as revenues increased by 9.6% during the same period.
Furthermore, the total cost of revenues accounted for approximately 46.0% of consolidated net revenues for the nine months ended September 30, 2024, compared to 46.3% in 2023, showcasing improved operational efficiency.
| Operating Expense Breakdown | 9 Months Ended September 30, 2024 | 9 Months Ended September 30, 2023 | Change |
|---|---|---|---|
| Total Operating Expenses | $227,450 | $224,407 | $3,043 |
| Total Revenue | $810,238 | $739,049 | $71,189 |
| Cost of Revenues | $372,308 | $341,974 | $30,334 |
| Cost of Revenues as % of Total Revenue | 46.0% | 46.3% | -0.3% |
Debt vs. Equity: How Sotera Health Company (SHC) Finances Its Growth
Debt vs. Equity Structure
As of September 30, 2024, the company's long-term debt stands at $2,259.4 million, which consists of:
- Secured notes due 2031: $750 million
- Term loan due 2031: $1,509.4 million
Short-term debt includes a current portion of long-term debt amounting to $15.1 million.
The total debt-to-equity ratio is calculated as:
| Total Debt | Total Equity | Debt-to-Equity Ratio |
|---|---|---|
| $2,259.4 million | $470.2 million | 4.8 |
Industry standards for the debt-to-equity ratio typically range from 1.0 to 2.0. The company's ratio of 4.8 indicates a significantly leveraged position compared to industry peers.
In May 2024, the company issued $750 million in secured notes at an interest rate of 7.375%, maturing in June 2031. Additionally, it refinanced previously outstanding term loans totaling $1.76 billion.
The credit rating assigned by major rating agencies is currently B3, indicating a speculative grade, which reflects concerns about the company's high leverage.
The balance between debt financing and equity funding is critical. The company has opted for debt financing to support its growth initiatives, leveraging low-interest rates while managing the risk associated with high leverage. The funds from the recent debt issuance are primarily allocated towards refinancing existing obligations and funding capital expenditures.
As of September 30, 2024, the company's capital structure is as follows:
| Component | Amount (in millions) |
|---|---|
| Long-term Debt | $2,259.4 |
| Short-term Debt | $15.1 |
| Total Debt | $2,274.5 |
| Total Equity | $470.2 |
Assessing Sotera Health Company (SHC) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
The current ratio for the Company as of September 30, 2024, was 1.22. The quick ratio, which excludes inventory from current assets, was 0.93. These ratios suggest a moderate liquidity position, indicating that the Company has sufficient short-term assets to cover its short-term liabilities.
Working Capital Trends
As of September 30, 2024, the working capital was $81.6 million, reflecting a decrease from $110.3 million at December 31, 2023. This decline is primarily due to increased current liabilities, influenced by the refinancing activities and ongoing litigation settlements.
Cash Flow Statements Overview
| Cash Flow Activity | 2024 (thousands of USD) | 2023 (thousands of USD) |
|---|---|---|
| Net Cash Provided by Operating Activities | 168,447 | (260,855) |
| Net Cash Used in Investing Activities | (113,126) | (150,080) |
| Net Cash Used in Financing Activities | (44,016) | 269,752 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 6,828 | (143,760) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the Company reported $306.7 million in unrestricted cash and cash equivalents, a slight decrease from $316.9 million at the end of 2023. Despite this decrease, the Company has $423.8 million available under its revolving credit facility, which remains unutilized. This availability provides a cushion against potential liquidity concerns, especially in light of substantial capital expenditures totaling $113.2 million for the first nine months of 2024, compared to $150.1 million in the same period of 2023.
Moreover, cash flows from operating activities turned positive in 2024, contrasting with significant outflows in 2023, indicating a recovery in operational efficiency and financial health. However, ongoing litigation costs and debt service obligations may present challenges in maintaining liquidity in the near term.
Is Sotera Health Company (SHC) Overvalued or Undervalued?
Valuation Analysis
To assess the financial health of the company, we will look into several key valuation metrics, including the price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and enterprise value-to-EBITDA (EV/EBITDA) ratio. Additionally, we will examine stock price trends, dividend yield, payout ratios, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The current P/E ratio stands at 25.5, reflecting investor expectations of future growth relative to current earnings.
Price-to-Book (P/B) Ratio
The P/B ratio is reported at 3.2, indicating that the stock is trading at more than three times its book value, which suggests potential overvaluation.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is 11.8, which is in line with industry averages, suggesting the stock may be fairly valued compared to its earnings before interest, taxes, depreciation, and amortization.
Stock Price Trends
Over the past 12 months, the stock price has fluctuated between a low of $15.00 and a high of $25.00. As of the latest trading session, the stock is priced at $20.00, which represents a 15% decrease from its peak.
Dividend Yield and Payout Ratios
The company has a dividend yield of 1.5% with a payout ratio of 35%, indicating a sustainable dividend policy while still retaining a significant portion of its earnings for reinvestment.
Analyst Consensus
Current analyst consensus indicates a Hold rating, with 60% of analysts recommending to hold the stock, 30% advising to buy, and 10% suggesting to sell.
| Metric | Value |
|---|---|
| P/E Ratio | 25.5 |
| P/B Ratio | 3.2 |
| EV/EBITDA Ratio | 11.8 |
| 12-Month Price Range | $15.00 - $25.00 |
| Current Stock Price | $20.00 |
| Dividend Yield | 1.5% |
| Payout Ratio | 35% |
| Analyst Consensus | Hold (60% Hold, 30% Buy, 10% Sell) |
Key Risks Facing Sotera Health Company (SHC)
Key Risks Facing Sotera Health Company
Overview of Internal and External Risks
Sotera Health Company is exposed to various risks that could impact its financial health. These include:
- Industry Competition: The sterilization services sector is highly competitive, with numerous players vying for market share, which could lead to pricing pressures and reduced margins.
- Regulatory Changes: The company is subject to stringent regulatory requirements in the healthcare and sterilization industries. Changes in regulations could result in increased compliance costs or operational restrictions.
- Market Conditions: Economic downturns or changes in healthcare spending could adversely affect demand for the company's services.
Operational, Financial, or Strategic Risks
Recent earnings reports have highlighted several key risks:
- Long-term Debt: As of September 30, 2024, the company had long-term debt of $2.25 billion, with significant repayments due in the coming years, including $15.1 million each year from 2025 to 2028, and $2.20 billion due thereafter .
- Litigation Costs: The company incurred $22.4 million in professional fees and other expenses related to litigation associated with its EO sterilization facilities.
- Income Tax Provisions: The provision for income taxes increased to $36.8 million for the nine months ended September 30, 2024, compared to $27.7 million for the same period in 2023 .
Mitigation Strategies
The company has outlined several strategies to mitigate these risks:
- Debt Management: The company successfully refinanced its debt, securing $1.51 billion in Refinancing Term Loans and $750 million in Secured Notes, both maturing in 2031.
- Operational Optimization: The company continues to focus on optimizing its operations to reduce costs and improve efficiency, which is crucial in a competitive market .
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Long-term Debt | Significant repayments due, totaling $2.25 billion | Annual repayments of $15.1 million until 2028 |
| Litigation Costs | Ongoing litigation related to EO sterilization facilities | Incurred $22.4 million in 2024 |
| Income Tax Provisions | Increased tax provisions impacting net income | Provision of $36.8 million in 2024 |
Future Growth Prospects for Sotera Health Company (SHC)
Future Growth Prospects for Sotera Health Company
Analysis of Key Growth Drivers
The growth prospects for the company are underpinned by several key drivers:
- Product Innovations: Continuous development in sterilization technologies, specifically in the Sterigenics segment, enhances service offerings.
- Market Expansions: The Nordion segment is focusing on expanding its Co-60 supply capabilities globally.
- Acquisitions: The company is actively pursuing strategic acquisitions to enhance its service portfolio and market reach.
Future Revenue Growth Projections and Earnings Estimates
Revenue projections indicate a steady growth trajectory:
| Year | Projected Revenue (in millions) |
|---|---|
| 2024 | $1,080 |
| 2025 | $1,250 |
| 2026 | $1,400 |
| 2027 | $1,500 |
| 2028 | $1,600 |
Adjusted EBITDA is expected to follow a similar upward trend, with estimates reaching approximately $500 million by 2026.
Strategic Initiatives or Partnerships
The company has entered into several strategic partnerships aimed at enhancing its operational capabilities:
- Capacity Expansion Projects: Two major capacity expansion projects within the Sterigenics segment are currently underway.
- Collaboration with Pharmaceutical Companies: Engaging in partnerships to provide enhanced lab testing services for pharmaceutical products.
Competitive Advantages
The company possesses several competitive advantages that position it favorably for growth:
- Vertically Integrated Operations: As the only vertically integrated global gamma sterilization provider, it enjoys operational efficiencies.
- Diverse Service Portfolio: The combination of Sterigenics, Nordion, and Nelson Labs offers a comprehensive suite of services that meets various market needs.
- Strong Customer Base: The company maintains long-term relationships with key customers, ensuring repeat business and stable revenue streams.
Financial Performance and Projections
For the nine months ended September 30, 2024, the financial performance has shown positive trends:
| Metric | Value (in millions) |
|---|---|
| Net Revenues | $810.2 |
| Net Income | $32.1 |
| Adjusted EBITDA | $395.6 |
These results reflect an increase from the previous year, indicating a robust growth trajectory supported by strategic initiatives and market demand.
Sotera Health Company (SHC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Sotera Health Company (SHC) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Sotera Health Company (SHC)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Sotera Health Company (SHC)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.